James Waldron
LightNews LightNews
jameswaldron.bsky.social
James Waldron
@jameswaldron.bsky.social
320 followers 600 following 10 posts
UK/EU Bureau Chief @ Fierce Biotech
Posts Replies Media Videos
jameswaldron.bsky.social
I spoke to corporate experts to find out why activist investors have biotechs in their sights...
www.fiercebiotech.com/biotech/why-...
Why 'emboldened' activist investors are taking the fight to biotechs
Whether it’s drug developers being pressured to wind down or investors accused of
www.fiercebiotech.com
July 2, 2025 at 2:07 PM
jameswaldron.bsky.social
With Big Pharmas backing out of the TIGIT space after making $6B in failed bets, where did it go wrong for the once-hot modality? And is there any hope left?
www.fiercebiotech.com/biotech/trou...
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | Once hailed as the future of immuno-oncology, it’s been a tough few months...
www.fiercebiotech.com
June 13, 2025 at 12:36 PM
jameswaldron.bsky.social
"We are committed to working collaboratively with Secretary Kennedy, HHS, BARDA and other members of President Trump’s administration as they evaluate their priorities," CEO Steven Lo told analysts...
www.fiercebiotech.com/biotech/vaxa...
Vaxart lays off 10% of staff after HHS unexpectedly demands halt to COVID vaccine trial
Vaxart has laid off 10% of its staff after the U.S. | Vaxart has laid off 10% of its staff after the U.S. government unexpectedly ordered the biotech stop work on a trial of its COVID-19 vaccine pill.
www.fiercebiotech.com
March 21, 2025 at 2:37 PM
jameswaldron.bsky.social
Novo Nordisk is shaking up its early-stage R&D structure. I spoke to CSO Marcus Schindler about why this isn't simply a "cost-cutting exercise" or a knee-jerk reaction to the CagriSema data
www.fiercebiotech.com/biotech/not-...
'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up
Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo Nordis...
www.fiercebiotech.com
March 20, 2025 at 2:30 PM
jameswaldron.bsky.social
Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here...
www.fiercebiotech.com/biotech/jpm2...
JPM25, Day 2: Trump admin health picks ‘like a box of chocolates’
Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. Yesterday saw some high-value dealma...
www.fiercebiotech.com
January 14, 2025 at 4:34 PM
jameswaldron.bsky.social
For the latest Fierce Biotech podcast, I caught up with Novo Nordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer
www.fiercepharma.com/pharma/novo-...
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to blockbuster drug semaglutide, which it sells as Ozempic, Wegovy and Rybelsus. | This...
www.fiercepharma.com
December 17, 2024 at 8:51 AM
Reposted by James Waldron
noahkonig.com
It's that time of year again - Biotech's Rotten Tomatoes of 2024

www.fiercebiotech.com/biotech/fier...

From @jameswaldron.bsky.social
Fierce Biotech's Rotten Tomatoes of 2024
Biotech experienced a year of mixed fortunes in 2024. | Fierce Biotech recounts the biggest biotech blunders and one inspiring intervention in the 2024 edition of Rotten Tomatoes.
www.fiercebiotech.com
December 16, 2024 at 9:54 PM